Webinar explains how to decrease needleto- needle time for Autologous Cell Therapies

The development of Autologous Cell Therapies is vastly different than traditional biopharmaceutical products, or even other cell and gene therapy products, and the complexities of this novel therapeutic treatment span the development pipeline.

One primary concern for patients who may be critically ill, or have compromised immune systems, is testing to ensure the biosafety of the cells prior to delivery back to patients. With patients awaiting their customized cell therapy treatments, timing is critically important.

Biosafety testing for Autologous Cell Therapies can be expedited with the proper instrumentation, regulatory knowledge, and scientific expertise.

During this recent webinar, our experts discussed relevant biosafety testing solutions to help rapidly deliver results for the patients to receive their modified cells and help support these new therapeutic approaches in the autologous cell therapy area, including:

• Rapid Sterility Testing
• Rapid Mycoplasma Testing
• Endotoxin Testing

Our experts discussed various aspects of these testing solutions, including instrumentation required, validation of the test methods, method suitability B&F requirements, timelines for results, and more.

If you are a Scientist, Manager, or Director involved with the development of an Autologous Cell Therapy product and you missed the live webinar mid-November, view here: https://event.on24.com/wcc/r/2639058/BFFD1365B5DEB83533C58A4061C1FA4D